What smart money is saying about Iradimed Corp.
IRMD
No fund has written a full thesis on Iradimed Corp. in our archive, but 3 fund letters report a position in it — most recently Granahan Investment Management Microcap Growth Strategy in September 2026.
Get an email when a fund buys, sells or pitches it
3
Reported positions
0
Bought
1
Sold
3
Letters
Position history
Between Q2 2026 and Q3 2026, 3 fund letters reported a position in Iradimed Corp. — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
| Q2 2026 | 2 | 0 | 1 | 0 |
Fund activity · 3 positions · 1 move
- September 2026
“Iradimed Corp. Core Growth 3.9%”
Iradimed Corp. - June 2026
“Several sales reflected valuation and sizing discipline. We trimmed iRadimed (IRMD) in early May: the position had grown beyond 5% of the portfolio, near-term earnings comparisons are demanding, and the valuation was extended, though the fundamental story remains intact as the company's new IV pump configurations carry list prices more than double the prior generation.”
Iradimed Corp. - June 2026
“IRadimed Corporation (Health Care, Core Growth) IRadimed declined modestly, creating a relative-performance headwind in an exceptionally strong market despite continued fundamental execution.”
62 more words on why — unlock Granahan Investment Management Microcap Growth Strategy’s full commentIradimed Corp.
Read the letters behind these Iradimed Corp. positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger